Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in ...
A partnership comprising TransCode Therapeutics and Quantum Leap Healthcare Collaborative has submitted an investigational ...
Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...
Participants will each receive a single intravenous infusion of AFTX-201 at doses determined from preclinical studies.
The FDA said it would take “decisive steps” to restrict non-approved drugs that use GLP-1 active pharmaceutical ingredients.
The FDA announced it planned to restrict use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, including those from Hims & Hers and other compounding pharmacies.“These actions are ...
The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...
FDA grants first emergency use authorization for an over-the-counter product for the prevention of NWS infestations in cattle ...
Vybrique is an oral film formulation of sildenafil, a phosphodiesterate-5 inhibitor, designed to dissolve on the tongue without the need for food or water.
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results